Evidence · Systematic review or meta-analysis
Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
- Bronchiolitis
- Infection and sepsis
- Infection prevention
- Mechanical ventilation
- Medical
- Nursing
- Respiratory
Summary
Systematic review and network meta-analysis of 15 randomised trials (over 18 000 infants) comparing monoclonal antibodies with placebo for prevention of RSV infection in infants and children at high risk. Outcomes included RSV-related infection and hospitalisation, ICU admission, supplemental oxygen and mechanical ventilation use, mortality and drug-related adverse events. Nirsevimab, palivizumab and motavizumab were associated with reduced RSV infection and hospitalisation, with some reductions in ICU admission and oxygen use, and no significant increase in adverse events; suptavumab showed no benefit. Relevant to PICU teams for understanding upstream prevention of severe bronchiolitis admissions.
Summary written for PICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to PICUlearn members, and Peeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.